Collagen Peptides, in Association with Vitamin C, Sodium Hyaluronate, Manganese and Copper, as Part of the Rehabilitation Project in the Treatment of Chronic Low Back Pain

What Was Tested

This randomized controlled trial paper looks at Copper (Supplement) in the context of chronic pain: fibromyalgia & crps.

Low back pain (LBP) is a frequent symptom.

Among the causes that can determine it, lumbar osteoarthritis plays an important role.

Oral supplementation with collagen peptides represents a new therapeutic possibility in osteoarthritis.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Sixty patients were recruited and randomly divided into two groups (Group A and B).

Group A performed only kinesitherapy, Group B carried out the same kinesitherapy combined with the daily administration of food supplements such as Fortigel®, Vitamin C, sodium hyaluronate, manganese and copper, during the whole treatment period.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Patients were evaluated at the time of recruitment (T0), at the end of the treatment (T1 - 3 weeks after T0) and 6 weeks after T1 (T2).

The outcome measures used were: Visual Analogue Scale (VAS), Oswestry Disability Index (ODI), and Short Form-12 (SF-12).

What Was Measured

Topics PubMed links to this paper include Ascorbic Acid, Chronic Pain, Collagen, Combined Modality Therapy, Copper, Exercise Therapy and Hyaluronic Acid.

The authors tagged it with the keywords Low back pain, McKenzie method, collagen peptides, hyaluronate sodium, oral supplementation and osteoarthritis.

What This Means in Plain Language

The paper is a randomized study of Copper (Supplement) in people with chronic pain: fibromyalgia & crps.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Endocrine, metabolic & immune disorders drug targets), a journal based in United Arab Emirates.

More context: the Copper (Supplement) compound page, Chronic pain: fibromyalgia & CRPS research.